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Abstract: The objective of this study was to create a clinically applicable mathematical model of immunotherapy for
cancer and use it to explore differences between successful and unsuccessful treatment scenarios. The simplified
predator-prey model includes four lumped parameters: tumor growth rate, g; immune cell killing efficiency, k; immune
cell signaling factor, λ; and immune cell half-life decay, μ. The predator-prey equations as functions of time, t, for normalized tumor cell numbers, y, (the prey) and immunocyte numbers, x, (the predators) are: dy/dt = gy – kx and dx/dt
= λxy – μx. A parameter estimation procedure that capitalizes on available clinical data and the timing of clinically
observable phenomena gives mid-range benchmarks for parameters representing the unstable equilibrium case in
which the tumor neither grows nor shrinks. Departure from this equilibrium results in oscillations in tumor cell numbers and in many cases complete elimination of the tumor. Several paradoxical phenomena are predicted, including
increasing tumor cell numbers prior to a population crash, apparent cure with late recurrence, one or more cycles of
tumor growth prior to eventual tumor elimination, and improved tumor killing with initially weaker immune parameters or smaller initial populations of immune cells. The model and the parameter estimation techniques are easily
adapted to various human cancers that evoke an immune response. They may help clinicians understand and predict
certain strange and unexpected effects in the world of tumor immunity and lead to the design of clinical trials to test
improved treatment protocols for patients.
Keywords: Adoptive, basal cell carcinoma, imiquimod, immune modulation, Lotka-Volterra, lymphoma, melanoma,
predator-prey, tumor infiltrating lymphocytes

Introduction

systematic analysis are reviewed in [3, 5, 7, 10].

Mathematical analysis of immune mechanisms
in general and of anti-tumor immunity in particular has a rich intellectual history [1-8]. Predatorprey equations have seemed to fit the problem
nicely since the time of Bell [4], and remain subject of active investigation in the 21st century[2,
8, 9]. With growth in knowledge about the intricacy of the immune system, complex systems of
10 to 20 coupled differential equations, often
nonlinear, have been developed to describe the
humoral and cellular immune responses, including changes in cell populations in response to
chemical signals arising from hormones, cytokines, and cellular debris [5, 10]. There can be
separate equations for each subtype of cell and
for concentrations of relevant chemical mediators [5]. Details of the immune system and its

Typically mathematical models have dealt with
anti-tumor immunity directed toward highly antigenic tumors arising from a single cell [5, 7].
They have shown the conceptual feasibility of
“tumor surveillance” by the immune system and
destruction of microscopic nascent tumors of
high antigenicity. However, there is a need for
models dealing with established tumors that
cause clinical cancer, in part because they have
evaded early tumor surveillance and have
grown to macroscopic sizes. These tumors, almost by definition, are weakly antigenic. The
theoretical potential for destruction of such larger, established tumors by treatments that
boost the immune response, such as adoptive
cell therapy [11-14], immune-modulating drugs
[15-18], and anti-cancer vaccinations [19-23]
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remains a subject of active investigation.
Although complex mathematical models involving many differential equations can provide useful insights into detailed mechanisms, they suffer from the need to specify a large number of
parameters. These values are difficult to estimate for cases of human disease, for which
relevant data are often non-existent. Some parameter values can be extrapolated from mouse
and hapten-carrier systems [5, 24], for which
results are often inconsistent among different
experiments [7]. Remaining unknown parameters must be set arbitrarily [5]. In this sense
there is a long leap from lab bench and laptop
to bedside. Hence there may be virtue in studying less complex mathematical systems, for
which parameters can be estimated from human clinical observations and experience, and
perhaps even individualized to particular molecular subtypes of cancer in particular types of
patients [25].
Accordingly, the goals of the present research
were to develop a simple and workable mathematical model of immunotherapy directed toward weakly antigenic, macroscopic tumors in
human beings and to explore theoretical differences between successful and unsuccessful
treatment scenarios and protocols. Ideally such
a model has enough terms to provide a reasonable approximation of reality but is simple
enough for its functioning and limitations to be
fully understood. Here we adopt a classical
predator-prey formulation of the tumor immunity
problem as a battle between immune cells and
tumor cells (predators and prey, respectively).
We note that the immune system, like an army,
includes soldiers with many ranks and roles,
organized into functional units. Although there
is, without doubt, virtue in detailed analysis to
understand and exploit mechanisms, there is
also value in predicting the outcome of a battle
in broader terms: the comparative sizes of the
opposing armies and their comparative fighting
effectiveness. In many cases these factors
alone are sufficient to predict the outcome as
an easy victory for one side or the other, or perhaps a long, back-and-forth struggle.
Methods
Model formulation
Consider one compartment in which a tumor
grows autonomously and in which tumor cells
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are killed upon contact with cytotoxic immune
cells (immunocytes, including lymphocytes and
activated macrophages). Let T denote the number of tumor cells and let L denote the number
of immune cells. The time rate of change in tumor cell numbers (dT/dt) is increased by cell
division and diminished by first-order spontaneous cell death, supplemented to a varying degree by immune mediated cell killing. The rate
of change in anti-tumor immune cells (dL/dt) is
driven by signals arising from the interaction,
represented by the product, TL, of existing tumor cells, T, and immune cells, L. Immune cells
also experience half life decay from death and
emigration. The corresponding model equations
as a function of time, t, are

dT
 gT  kL
dt
dL
 TL  L
dt

(1a)

(1b)

Equation (1a) has the general structure dT/dt =
net replication rate in absence of tumor immunity – rate of killing by immunocytes. Equation
(1b) has the general structure dL/dt = recruitment from cell-cell signaling – half life removal.
Constants, g, k, , and μ are lumped parameters
representing the overall effectiveness of component processes. Constant, g, represents net
tumor cell growth minus decay. That is, g = g1 –
g2, where g1 is the first order rate constant for
cell division, and g2 is the first order rate constant for spontaneous tumor cell death caused
by processes other than immune mediated killing. Constant, k, represents the average killing
effectiveness of all immune effector cells, L,
that is, an average soldier in the army, including
those in non-combat roles. Constant, , represents positive feedback on lymphocyte recruiting. The positive feedback may result from release of tumor antigens or from release of cytokines by active lymphocytes. The half life decay
of immune cells, L, is denoted μ, representing
spontaneous death and emigration. Modeling
tumor cell killing by immune cells in expression
(1a) as kL, rather than a more traditional formulation [1], such as kLT or kLT/(K+L), enhances
simplicity and may be more reflective of nonrandom targeting of tumor cells by lymphocytes.
Such purposeful targeting would tend to make
killing rates proportional to the number of lymphocytes until all targets are destroyed, at which
Am J Cancer Res 2012;2(2):204-213
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time killing abruptly ends.
Initial conditions describe the state of the tumor
at the time of diagnosis. T0 is the initial pretreatment tumor cell population. L0 is the initial
immune cell population within the tumor compartment, where L0 << T0 in un-rejected and
clinically troublesome tumors. To normalize for
various sizes of tumors at the time of diagnosis
(Others have modeled different growth rates
and cytokinetics for tumors of grossly different
size, ranging from one nascent cell to 107 or
more cells. Here the size range is much more
restricted to tumors the size that come to clinical attention, say ~ 1 to 100 ml at diagnosis, in
which case it is reasonable to consider a single
clinical growth rate at this stage.), let y = T/T0
represent the relative tumor size, and let x = L/
T0 represent the relative immune cell density
within the tumor. Then

dy
 gy  kx
dt
dx
  xy  x
dt

(2a)

(2b)

where the new constant, λ = T0, describes the
net effects of positive feedback signaling. The
initial conditions for equations (2) are y0 = 1,
representing the size of the tumor at diagnosis,
and x0, representing the initial immune cell density, as determined for example by quantitative
microscopic analysis, flow cytometry, or histochemistry of excised tumors or biopsy specimens. Here the rate of change in immunity is
influenced by four factors: net spontaneous
growth of the tumor, g, tumor killing ability of
immunocytes, k, the ability of immunocytes, λ,
to call for help and increase their numbers in
the battle space, and the spontaneous rate, μ,
of death or emigration of immunocytes from the
battle space.
Limiting cases
When t = 0, then y0 = 1, and when k = 0 (no
tumor cell killing), y = egt with unopposed tumor
growth. When λ = 0 and k ¹ 0 there is tumor cell
killing by the original L0 lymphocytes only, but
no recruiting of additional immune cells. In this
case, the immunocytes decay exponentially so
that x = x0e-μt, and in turn, dy/dt = gy - kx0e-μt,
showing slower growth than the unrestricted
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case, because of time limited tumor killing initially.
Mid-range, reference parameters
A most interesting and useful case is that of an
unstable steady-state, in which the tumor neither grows nor shrinks in size. This condition
represents a stalemate in which neither the
immune system or the tumor gains the upper
hand and is a useful starting point for theoretical explorations of strategies and effects. In this
case we have

dy
 gy0 k0x0  0 and y0 = 1, so that k0=g/x0. (3)
dt
Also, in the steady state we must have no net
change in immune cell numbers, hence

dx
 0 x0 y0  x0  0 so that λ0 = μ.
dt

(4)

These equilibrium values of k0 and λ0 represent
the middle of the biologically relevant domain of
immune system activity. Their numerical values
can be estimated from clinical observations in
terms of g, x0, and μ as follows, to obtain a starting point for simulations.
Parameter estimation for conditions prior to
treatment
Estimation of g
Rates of disease progression in patients with
the same type of cancer vary, even among cancers of the same cell type and stage. Suppose
that average tumors are held in check, compared to more aggressive ones, at least partially
by immune mechanisms. This state of affairs is
suggested by clinical data on the emergence of
tumors during immune-suppressive therapy for
organs transplants [26, 27], and also by the
correlations of tumor associated lymphocyte
numbers with clinical prognosis [28-30]. In this
case one can estimate the unrestricted growth
rate, g, from the doubling time of more rapidly
progressing tumors in a given class. For minimally immunogenic tumors dy/dt ≈ gy, or dy/y ≈
gdt, from which, after integration, y ≈ egt. For
doubling time t2, it follows that 2 ≈ egt2, or g ≈ ln
(2)/t2 ≈ 0.69/t2. For example, if more aggressive tumors of a particular cell type double in
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170 days after diagnosis, then we would have g
= 0.004 days-1.

sheets themselves using only arithmetic functions. For

Estimation of x0

dx
dy
 f1(x, y) ,  f2 (x, y)
dt
dt

Parameter x0 can be obtained from biopsies of
human tissue, as determined by quantitative
microscopic analysis, flow cytometry, or histochemistry of excised tumors or biopsy specimens. Microscopically detectable lymphocytes
are rare but detectable in many tumors [28-30],
suggesting a relative density on the order of
1/1000.
Estimation of k0
For the equilibrium condition (3) we must have
k0 = g/x0. For example, if g = 0.004 days-1, x0 =
0.001, this implies k = 4 tumor cells killed per
lymphocyte per day. From considerations of
practical biology a lymphocyte can only kill a
handful of tumor cells per day [5]. Hence values
of 1 < k < 10 are quite reasonable.
Estimation of μ
Normal biology and clinical experience set limits
on the value of lymphocyte decay, μ. The offset
time for moderate to severe viral infections,
which are combated by cellular immunity, is on
the order of a few days or about one week. The
exponential decay of the induration of a PPD
(purified protein derivative) test for tuberculosis,
also mediated by cellular immunity, is also a few
days to one or two weeks [31]. Thus in the absence of stimulation (λxy = 0) we would have
dx/dt = –μx or , x ≈ e-μt . For half time t1/2, it follows that 1/2 ≈ e-μt1/2, or μ ≈ ln(2)/t1/2 ≈ 0.69/
t1/2. For example, if the offset of a cellular immune response has a half life of 7 days, then μ
≈ 0.1 days-1.
In this way mid-range orders of magnitude for
parameters g, x0, and μ, and in turn k0, and λ0
can be determined from clinical data. It is not
necessary to have expensive equipment, animal
models, cell cultures, large laboratories, or
mountains of research money.
Numerical methods
Equations (2) were integrated numerically using
the simple Euler method implemented in Visual
Basic code within an Excel spreadsheet on an
ordinary personal computer. Optionally, necessary computations can be done within spread-
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(5)

x (t   t )  x (t )  f 1  t ,
and y ( t   t )  y ( t )  f 2  t .

(6)

Given initial conditions at t = 0, one can trace
the evolution of the variables x and y in time, in
a “marching solution”, for which stability and
accuracy are ensured by using a sufficiently
small value of Δt, such as 0.01 day. Increasing
or decreasing Δt without effect on the results
confirms that a sufficiently small value was chosen for Δt.
Results
Consider a hypothetical human tumor, such as
a basal cell carcinoma of the skin, having properties shown in Table 1, estimated from clinical
observations, as just described.
Table 1. Representative model parameters at
equilibrium.
ParamePrimary
Description
ter
value
y0

1

x0

0.001

g

0.004 days-1

k

4 days-1

λ

0.1 days-1

μ

0.1 days-1

Relative tumor cell
count or size
Relative density of
immune cells
Unopposed tumor
growth constant in
y = y0egt
Immune cell killing
effectiveness tumor
cells/lymphocyte/day
Immune cell signaling constant lymphocytes/tumor cell/day
Decay constant for
immunocytes in
x = x0e-μt; λ=0

Figure 1A illustrates changes in tumor size as a
function of time as the cell signaling parameter,
λ, is increased from the steady-state value of
0.1 days–1. The horizontal axis for this model
represents 2000 days or about 5.5 years. For
simplicity, we assume that average tumor
growth rate, g, is not affected by immunotherapy and that the tumor cells are equally susceptible to cytotoxic cells. The dashed horizontal
line represents the unstable steady state equiAm J Cancer Res 2012;2(2):204-213
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Figure 1. A. Tumor growth and decay with departure of cell signaling parameter, λ, from its equilibrium value in the
positive direction for the primary model in Table 1. B. Effective tumor elimination in three months with λ = 0.19, less
than twice the equilibrium value.

librium, in which immune mediated tumor cell
killing exactly balances spontaneous tumor
growth. A 10 percent increase in λ produces an
initial decline in tumor cell numbers, followed by
three cycles of re-growth, and then a precipitous
population crash with tumor elimination. Oscillatory patterns are consistent with classical
swings in predator-prey populations [1, 4].
Sharper and earlier population declines happen
as λ approaches 1.7 times the steady state
value. However, late re-growth to more than
double the original volume occurs before the
tumor is eliminated by the immune response.
Late recurrences at 2 to 5 years for λ near 0.17
are characteristic of many cases of clinical cancer. The recurrences in Figure 1A, however, are
not caused by tumor escape mechanisms, tumor cell heterogeneity, or evolution of tumor cell
resistance [32, 33]. Instead they result solely
from the dynamics of the predator-prey system
with a constant state of immune system activation. In all cases shown the tumor is eventually
destroyed when cell signaling, λ, is increased
above the steady-state equilibrium value.
When cell signaling effectiveness, λ, is 0.18 or
greater (filled circles) there is steady decline of
tumor cell numbers to zero, with complete and
irreversible elimination of the tumor. There appears to be a threshold near λ = 0.18, which
when crossed causes tumor population to crash
promptly without oscillation. When λ = 0.179
(open circles) there is late re-growth. However,

208

when λ = 0.181 there is complete and permanent tumor elimination. The difference in λ between the steady-state with λ = 0.1 and highly
effective therapies with λ > 0.18 is less than a
factor of two. The trajectory of tumor elimination
in three months for λ = 0.19 is illustrated in Figure 1B.
Some interesting and counterintuitive dynamic
phenomena happen when the cell signaling
parameter, λ, is reduced from its unstable equilibrium value of 0.1 day-1, as shown in Figure
2A. Here, progressive weakening of cell signaling causes accelerated tumor growth initially, as
would be expected. However, with continuing
nonzero values of feedback, λ, and normal, active immune mechanisms, the tumor size eventually reaches a threshold at which the tumor
cell population crashes to zero, with complete
tumor elimination. The cost of this indirect strategy is that more tumor growth is needed to trigger or provoke an intense anti-tumor immune
response. This phenomenon is explained by the
dependence of dx/dt on the product (LT or xy) of
both tumor and immunocyte population numbers. Yet such dependence is what would be
expected from the biology of immunity in general. The antigen dose matters in provoking effective anti-tumor immunization [34]. Bacterial
infections, similarly, must reach a certain size
before attracting large numbers of inflammatory
cells. The immunocyte population peaks in Figure 2B demonstrate responsiveness of the sys-
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Figure 2. A. Tumor growth and decay with departure of cell signaling parameter, λ, from its equilibrium value in the
negative direction for the primary model in Table 1. B. Time domain trajectories of relative immune cell number, x =
L/T0, for the case λ = 0.09, showing classical peaks in response to increasing tumor cell numbers.

Figure 3. A. Tumor growth and decay with departure of killing parameter, k, from its equilibrium value in the positive
direction for the primary model in Table 1. B. Tumor growth and decay with departure of killing parameter, k, from its
equilibrium value in the negative direction for the primary model in Table 1.

tem to increasing cell numbers. Relatively large
changes in immune cell numbers occur in response to relatively modest changes in tumor
size. The combined results in Figure 2 suggest
the potential robust nature of anti-tumor immunity.
Figures 3 and 4 illustrate similar time trajectories of tumor population numbers for departures of the model parameters k and x0 from the
unstable equilibrium state. The patterns of tu-
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mor growth and regression are quite similar to
those for manipulations of cell signaling
strength, λ. Both stronger and weaker cell killing
effectiveness can lead to tumor elimination,
preceded in some cases by one or more oscillations in population numbers. As before, the robustness of the tumor immunity system is highlighted by the large range of cases in with complete tumor elimination can happen, provided
one is willing to tolerate some initial tumor
growth.

Am J Cancer Res 2012;2(2):204-213
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Figure 4. A. Tumor growth and decay with departure of immunocyte density, x0, from its equilibrium value in the positive direction for the primary model in Table 1. B. Tumor growth and decay with departure of immunocyte density, x0,
from its equilibrium value in the negative direction for the primary model in Table 1.

The range of variation in killing effectiveness, k,
needed to demonstrate the various dynamic
behaviors, however, is much greater than the
range of variation in cell signaling, λ. Order of
magnitude increases in k (and also x0) are
needed to produce similar qualitative effects as
achieved by the doubling of λ. However, similar
patterns appear. When killing parameter k is
increased from the equilibrium state there is an
initial fall in tumor cell numbers. However,
smaller increases in k that are insufficient to
produce tumor elimination directly are followed
by oscillations of increasing amplitude until at
killing threshold is reached. The killing threshold
is lower for larger values of k. Ultimately, as k is
increased further, the threshold tumor size is
exceeded under the initial conditions. On the
other hand, if k is diminished, tumor growth
must occur before conditions develop that provoke a lethal trajectory for the tumor. Interestingly, extreme departures of k from its equilibrium value in either direction can provoke
prompt tumor elimination. The cost in the case
of weaker tumor cell killing is an approximate
doubling of the original tumor volume before a
population crash.
A similar phenomenon happens in Figure 4
when pre-existing immune cell numbers are
altered at time zero. In the thought experiments
represented here we assume equilibrium conditions for the primary model with x0 = 0.001,
representing one immune cell for every one
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thousand tumor cells. Then at time zero the
number of immune cells is abruptly changed to
a different value, either greater or less than
0.001. For example with adoptive immunotherapy [13, 14] the value of anti-tumor immune
cells could be suddenly increased. Alternatively,
a form of treatment that happened to be toxic to
immune cells locally but not to tumor cells could
have the opposite effect. After time zero immune cell numbers are free to change in response to cell signaling and half life decay.
A greater than 10 fold increase in initial immunocyte numbers is required to produce complete tumor eradication, starting at the equilibrium state. Amazingly, a strategy of selectively
reducing immune cell numbers for a short time,
provoking an initial burst of tumor growth, also
seems to be effective in triggering tumor eradication. This concept of a strategic retreat, as if
drawing the enemy out, followed by a vigorous
counterattack, is far from intuitive in clinical
oncology, but is suggested as a possible winning strategy by the mathematics. Such a strategy may not be as outlandish as it may at first
seem. For the scenarios in Figure 4B, in which
tumor growth is required before tumor elimination, tumor cell numbers reach no more than 4
times that at the time of diagnosis. Thus a 1 cm
diameter tumor mass need grow only to the
cube root of 4 or 1.6 cm diameter before conditions are ripe for its elimination. In many clinical
situations this would be an acceptable amount

Am J Cancer Res 2012;2(2):204-213
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of continued growth, if one had some assurance
and understanding that tumor elimination would
eventually happen.
Discussion
Immunotherapy is appealing because immune
cells efficiently kill target cells with minimum
destruction of normal neighboring cells. However, the time course of immunotherapy is
unlike that of conventional chemotherapy. Tumor killing happens quickly at the end of the
treatment period, rather than gradually over
time. With immunotherapy time is required to
recruit sufficient numbers of cytotoxic lymphocytes and their allies before the still dividing
tumor cells are actively destroyed. A very small
population of initial lymphocytes can be sufficient to start a positive feedback cycle that ultimately results in tumor elimination, provided
sufficient time is allowed for immune cell recruitment. Indeed, tumor elimination seems
quite possible via a variety of strategies that
manipulate parameters describing the balance
of power in a predator-prey system.
The complex, and sometimes unexpected, behavior of predator-prey systems describing antitumor immunity has been noted by others [5-8].
Here we describe several interesting dynamical
phenomena, including oscillations in tumor cell
numbers, sharp thresholds between failed and
completely successful therapy, improved success after weakening of anti-tumor response
parameters, initial tumor growth as a prelude to
early tumor elimination-even the potential utility
of deliberately provoking tumor growth in the
presence of a functioning immune system as a
strategy for long term cure.
Focusing on the simplest possible predator-prey
equations for tumor immunity can help to provide understanding of the relevant cell-cell interactions and their various counterintuitive twists.
With only two equations, two variables, four parameters, and reasonable initial conditions one
can begin to reconstruct the chains of causation
leading to growth, oscillations, or decay in cell
population numbers. The phenomena described
here are not related to evolution of resistance,
escape mechanisms, or any changes in tumor
biology. They are simply the result of predatorprey dynamics. The clinically oriented mathematical models of Equations (1) and (2) may
help to make such dynamics easier to recognize
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and also easier to exploit in human cancers.
Adoptive immunotherapy [6, 13, 14], for example, can be represented by a boost in x0 at the
beginning of treatment. Drug therapy with immune modifiers such as imiquimod [18] can be
represented by a boost in λ. Conventional
chemoradiation treatment can be represented
approximately by replacing the positive growth
constant, g, with g = –g. Each cell cycle would
then lead to death rather than duplication of the
dividing cell. (Strictly, if g = g1 –g2 , then g = –
(g1 + g2)) Modifying parameters g, k, μ, and λ in
a systematic way over time can be done to
simulate combined treatment protocols, including various sequences of conventional chemotherapy or radiation, followed by immunotherapy [35, 36], targeted radiation to specific tumor masses that spares systemic damage to
the patient’s immune system, possible dose
fractionation schemes, occasional drug holidays, etc. Initial estimates of model parameters
for a particular type of cancer can be refined on
the basis of ongoing clinical experience in a
particular practice setting.
The robust nature of anti-tumor immunity suggested by Figures 1 through 4, illustrating the
wide range of conditions resulting in complete
tumor elimination, is contrary to the past reputation of immune therapy for cancer as being hit
or miss, only occasionally successful, inconsistent, and most suitable as a last ditch effort
when traditional treatments fail [11, 12, 37].
However, the same modeling results can help to
explain how thoughtful observers could have
reached such conclusions. Equations (1) and (2)
imply that it is necessary to maintain consistent
immune stimulation for up to several years and
in many cases to tolerate noticeable tumor
growth before a killing threshold is reached.
Based upon experience with conventional chemotherapy, however, oncologists would tend to
interpret continued tumor growth as a sign that
immunotherapy is not working, and it would be
discontinued. Early discontinuation of immune
therapy would clearly lead to failure, providing
evidence that such therapy is not effective.
Mathematical models suggest that continued
growth of the tumor may be necessary for immune therapy to work, so that the product xy or
LT reaches a critical threshold. Thus predatorprey modeling may have a positive conceptual
or intellectual impact by justifying patience and
inhibiting the human impulse to stop immune

Am J Cancer Res 2012;2(2):204-213
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therapy too early.
Simplified predator-prey models may be especially useful if parameter estimation can be customized for particular types of human cancer,
for subpopulations of cancer patients with a
particular cell type and stage of cancer, or perhaps even for individual patients. Sophisticated
and expensive research personnel and equipment are not needed to estimate parameters g,
k, λ, x0, and μ in Equations (2). Astute clinical
observations, a calendar, and routine histopathological observations available in most hospitals are all that is needed. Both the model and
the parameter estimation techniques are easily
adapted to various human cancers that evoke
an immune response.
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